Novel biomarkers for anticancer therapy PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel biomarkers for anticancer therapy PDF full book. Access full book title Novel biomarkers for anticancer therapy by Hongtao Xiao. Download full books in PDF and EPUB format.
Author: Hongtao Xiao
Publisher: Frontiers Media SA
ISBN: 2832513859
Category : Science
Languages : en
Pages : 428
Get Book
Book Description
Author: Hongtao Xiao
Publisher: Frontiers Media SA
ISBN: 2832513859
Category : Science
Languages : en
Pages : 428
Get Book
Book Description
Author: Jinghua Pan
Publisher: Frontiers Media SA
ISBN: 2832525490
Category : Medical
Languages : en
Pages : 493
Get Book
Book Description
Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy.
Author:
Publisher: Frontiers Media SA
ISBN: 2832541933
Category : Medical
Languages : en
Pages : 261
Get Book
Book Description
This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.
Author: Vered Stearns
Publisher: Springer
ISBN: 3319229095
Category : Medical
Languages : en
Pages : 279
Get Book
Book Description
This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment(s) for individual patients.
Author: Sherry X. Yang
Publisher: CRC Press
ISBN: 1000367533
Category : Medical
Languages : en
Pages : 494
Get Book
Book Description
This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.
Author: Adeeb Shehzad
Publisher: Springer Nature
ISBN: 9811657599
Category : Medical
Languages : en
Pages : 372
Get Book
Book Description
This book illustrates the basics and underlying molecular machinery of cancer cells and biochemical assays that detect the type and stage of cancer through cell signaling biomarkers. It starts with a brief introduction to cancer biomarkers and addresses technologies for identifying and validating cancer biomarkers, biomarkers for cancer drug development, prognostic and diagnostic biomarkers, and microbiome as cancer biomarkers. It reviews predictive biomarkers for anticancer drugs, biomarkers in cancer survival and drug resistance, biomarkers in tumor recurrence and metastasis, the role of the biomarker in immunotherapy and personalized medicine, and the development of a novel cancer biomarker. Finally, this book also underpins the role of nanotechnology in the use and detection of cancer biomarkers for enhanced sensitivity and specificity. Lastly, it discusses the challenges with biomarkers in cancer drug discovery and development. This volume is an indispensable tool for researchers working in the field of cancer and also for clinical oncologists.
Author: Shivaani Kummar
Publisher: Academic Press
ISBN: 0128125705
Category : Medical
Languages : en
Pages : 234
Get Book
Book Description
Novel Designs of Early Phase Trials for Cancer Therapeutics provides a comprehensive review by leaders in the field of the process of drug development, the integration of molecular profiling, the changes in early phase trial designs, and endpoints to optimally develop a new generation of cancer therapeutics. The book discusses topics such as statistical perspectives on cohort expansions, the role and application of molecular profiling and how to integrate biomarkers in early phase trials. Additionally, it discusses how to incorporate patient reported outcomes in phase one trials. This book is a valuable resource for medical oncologists, basic and translational biomedical scientists, and trainees in oncology and pharmacology who are interested in learning how to improve their research by using early phase trials. Brings a comprehensive review and recommendations for new clinical trial designs for modern cancer therapeutics Provides the reader with a better understanding on how to design and implement early phase oncology trials Presents a better and updated understanding of the process of developing new treatments for cancer, the exciting scientific advances and how they are informing drug development
Author: Gw Sledge
Publisher: Clinical Pub
ISBN: 9781846920660
Category : Breast
Languages : en
Pages : 0
Get Book
Book Description
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author: Mu Wang
Publisher: BoD – Books on Demand
ISBN: 9535125052
Category : Medical
Languages : en
Pages : 262
Get Book
Book Description
The use of biomarkers in basic and clinical research has become routine in many areas of medicine. They are accepted as molecular signatures that have been well characterized and repeatedly shown to be capable of predicting relevant disease states or clinical outcomes. In Role of Biomarkers in Medicine, expert researchers in their individual field have reviewed many biomarkers or potential biomarkers in various types of diseases. The topics address numerous aspects of medicine, demonstrating the current conceptual status of biomarkers as clinical tools and as surrogate endpoints in clinical research. This book highlights the current state of biomarkers and will aid scientists and clinicians to develop better and more specific biomarkers for disease management.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309157277
Category : Medical
Languages : en
Pages : 335
Get Book
Book Description
Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
